BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities
Creates 120 new full-time jobs to support U.S. manufacturing of BeOne's innovative oncology medicines and deep clinical pipeline
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will increase BeOne's production capacity to manufacture its medicines and is expected to create approximately 120 new full-time jobs. The investment supports the continued advancement of BeOne's deep oncology pipeline of more than 35 clinical and commercial-stage assets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723679184/en/ BeOne Medicines' biologics manufacturing facility and clinical R&D center of excellence at the Princeton West Innovation Campus in Hopewell, NJ.
